IPO Advisory

IPO Research - IPO Boutique



Home

Subscriptions



Company
Symbol
Price
Shares
Trade Date
OncoMed PharmaceuticalsOMED
[ Nasdaq ]
17.004.8 millionJuly 18 2013
Underwriter(s):
Jefferies, Leerink Swann
Co-Manager(s):
Piper Jaffray, BMO Capital Markets
Industry:
Health Care
Employees:
80
Founded:
 
Address:
800 Chesapeake Drive, Redwood City, CA 94063
Phone:
650-995-8200


For IPO Boutique's "scale of 1 to 5" BUY rating on OncoMed Pharmaceuticals, and our comprehensive analysis, click the "Buy Market Research" link above.




About (adapted from prospectus):
OncoMed is a clinical development-stage biopharmaceutical company focused on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells, or CSCs. Their approach has been to target CSCs, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. Common cancer drugs target bulk tumor cells but have limited impact on CSCs. OncoMed's product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, and also impact bulk tumor cells.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus..


IPO Boutique aggregates information on public companies and private companies, such as "OMED" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.




Need a recommendation?
Visit our Testimonials page and see over 200 investors singing our praises.



Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2014 IPO Boutique. All Rights Reserved